Top in GI: Young-onset colorectal cancer; fecal immunochemical testing guidance
Researchers have identified higher rates of young-onset colorectal cancer mortality among patients in the Midwest and Great Lakes regions.
In an interview with Healio, study coauthor Blake Buchalter, PhD, MPH, postdoctoral fellow in the department of quantitative health sciences at the Cleveland Clinic Lerner Research Institute, highlighted key takeaways from the study and detailed future research directives. It was the top story in gastroenterology last week.
Another top story was about new guidance from European societies on the use of fecal immunochemical testing in patients with suspected colorectal cancer.
Read these and more top stories in gastroenterology below:
Researchers identify higher rates of young-onset CRC mortality in Midwest, Great Lakes regions
Researchers have discovered geographic patterns of mortality rates among patients with young-onset colorectal cancer in the United States, according to findings published in Gastroenterology. Read more.
European societies release joint guideline for use of FIT in colorectal cancer diagnosis
The Association of Coloproctology of Great Britain and Ireland and the British Society of Gastroenterology have published a joint guideline for the strategic use of fecal immunochemical testing in people with suspected colorectal cancer. Read more.
Prenatal exposure to endocrine-disrupting chemicals tied to ‘NAFLD epidemic’ in children
Prenatal exposure to endocrine-disrupting chemicals may be a cause of increased incidence of nonalcoholic fatty liver disease in children, according to a study published in JAMA Network Open. Read more.
Top news on NAFLD, NASH: cases in children, quality of life concerns, treatment updates
Healio handpicked its top stories on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, which highlight risks for children with NAFLD, how fatigue relates to quality of life, treatment with resmetirom and more. Read more.
No difference in HCC risk between tenofovir, entecavir for chronic HBV infection
There was no clinically meaningful difference in the risk for hepatocellular carcinoma between patients taking tenofovir vs. entecavir to treat chronic hepatitis B virus infection, according to study results published in JAMA Network Open. Read more.